Physician profile
Madeleine E Gantz
NPI 1821526674
$3,392.51
in general payments reported to CMS, 2019-2025
21 companies · $776 in 2025
The $776 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $232 · 2022: $845 · 2023: $699 · 2024: $841 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,235 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.47 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,002.85 | 2021-2025 | |
| Merz North America, INC. | $538.45 | 2021-2024 | |
| Revance Therapeutics, INC. | $368.40 | 2025 | Daxxify |
| Galderma Laboratories, L.P. | $240.94 | 2022-2025 | Nemluvio, Dysport |
| Almirall LLC | $204.35 | 2022-2023 | Seysara |
| Ucb, INC. | $119.90 | 2023-2025 | Briviact, Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $105.99 | 2023 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $104.07 | 2023 | |
| Pfizer INC. | $92.08 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $91.00 | 2023 | Dupixent, Libtayo |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Sun Pharmaceutical Industries INC. | $76.71 | 2022 | |
| Incyte Corporation | $75.73 | 2023-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $62.06 | 2022-2025 | Cabtreo, Arazlo |
| Allergan, INC. | $57.29 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.00 | 2022-2023 | Taltz, Olumiant |
| Leo Pharma INC. | $39.21 | 2022-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.34 | 2023 | Spevigo |
| Mayne Pharma Commercial LLC | $21.89 | 2025 | |
| Arcutis Biotherapeutics, INC. | $19.48 | 2023 | |
| Solta Medical, A Division of Bausch Health US, LLC | $17.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeleine Gantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.